Board of Directors

Photo of Dr Frank Armstrong (Non-Executive Chairman)Dr Frank Armstrong (Non-Executive Chairman) joined the Company on 1 September 2014. Frank has previously led Medical Science and Innovation (MSI) in R&D at Merck Serono, Worldwide Development at Bayer and the Worldwide Medical Organisation at Zeneca. He has also been the CEO of a number of life sciences companies and has extensive experience of medical and product development in large and small company environments, leading successful product approvals in the US and EU across a range of therapeutic areas. Frank has been the CEO of five biotechnology companies (public and private) and was CEO of Fulcrum Pharma, before it was sold to private equity. In 2007, he led the sale of 454 Life Sciences for CuraGen to Roche for a consideration of $154 million. Frank has experience acting as chairman and non-executive director in the UK and USA with both private companies and a NASDAQ listed company as well as being chairman of a charitable institution. Frank has been non-executive chairman of AIM listed Summit plc (LSE: SUMM) since June 2013 and is also a non-executive director of Mereo BioPharma plc.

Photo of Dr Neil Murray (CEO)Dr Neil Murray (CEO) co-founded the Company in 2010 and has over 25 years' experience in the pharmaceutical industry with experience of drug development, business growth and general management. He has held a variety of senior operational, commercial and R&D positions including as Global Director for Sales and Marketing with Solutia's Pharmaceutical Services business. Prior to joining Solutia he was Director of Chemical Development at Vernalis (formerly Vanguard Medica) with additional responsibility for management of the company's research portfolio. He was also European Business Development Director for SigmaAldrich before which he was External Projects Director at GlaxoWellcome with responsibility for the company's external development science. He has extensive experience of drug discovery and development and commercialisation in large and small companies across a wide range of therapeutic areas.

Photo of Dr Peter Jackson (Non-Executive Director)Dr Peter Jackson (Non-Executive Director) is a co-founder of the Company and previously served as Executive Chairman before becoming a Non-Executive Director in September 2014. In 2007, Peter founded the Company's predecessor company Bradford Pharma. From 2005 until 2010, Peter was founder and CEO of Reaxa, exploiting chemical catalyst technology for the production of drugs with lower levels of impurities to meet stricter quality standards. He is founder and Non-Executive Director of two other biopharma ventures, ADC Biotechnology focused on production of new antibody-based cancer therapeutics, and Yprotech Ltd (formally Yorkshire Process Technology), focused on development of new chemical processes for pharmaceuticals and agrochemicals. Peter has over 25 years' experience in the sector, holding senior executive roles as commercial Director then head of Avecia's Pharmaceutical Products business unit, following senior commercial and R&D positions at Zeneca and ICI.

Photo of Norman Molyneux (Non-Executive Director)Mr Norman Molyneux (Non-Executive Director) was previously the CFO of the Company before becoming a Non-Executive Director in September 2014. Norman is a qualified Chartered Management Accountant and has 15 years’ experience in arranging early stage business angel and venture capital funding. Following training in accountancy with GKN, he joined PriceWaterhouseCoopers, working on many consultancy assignments with both SME and multinational companies. Following this, he returned to industry with Director roles in the paper manufacturing and food manufacturing sectors in the UK. In 2000, Norman founded Acceleris Capital Limited, an FCA regulated fund management and corporate finance firm specialising in EIS-led investment transactions. Norman holds numerous Directorships fulfilling both executive and non-executive positions.

Photo of Peter McPartland (Non-Executive Director)Mr Peter McPartland (Non-Executive Director) has been Non-Executive Director of the Company since October 2010. A graduate pharmacologist, he worked for six years as an investment analyst before joining Schroder Ventures (now Permira) in 1988. In 1994 Peter became a co-founder and general partner of SV Life Sciences (SVLS). From 1998 he began to develop his own personal interests while maintaining a part-time role at SVLS, leaving that firm in 2007 to become an independent venture capital consultant. During his spell at SV/SVLS he was a director of a number of leading companies in the field, including Shire Pharmaceuticals, Chiroscience and Triangle Pharmaceuticals.

Photo of Dr Bernhard Kirschbaum (Non-Executive Director)Dr Bernhard Kirschbaum (Non-Executive Director) joined the Board in January 2016. Bernhard has over 25 years' experience in pharmaceutical research and drug development, having held leadership roles at Merck/Merck Serono, Sanofi-Aventis, Aventis and Hoechst Marion Roussel. He has expertise in a broad range of disease areas including oncology, immuno-oncology, immunology, neurological disorders and cardiometabolic diseases. In the eight years to 2013, he worked at Merck/Merck Serono, becoming a member of the Board and Executive Vice-President, Global Research & Early Development. He was responsible for a budget of 1 billion euros and a global team of over 2,500 associates. In his last three years at Merck Serono, he led the successful growth of the company's R&D portfolio, with over 70 programs, doubling the number of phase II assets in this period. Dr Kirschbaum is currently Chairman of Protagen Diagnostics and a board member of BioMedX and OMEICOS Therapeutics.

Photo of David Lawrence (Non-Executive Director)David Lawrence (Non-Executive Director) joined the Board in May 2016. David has over 25 years' experience in the biotech and pharmaceutical industries with a strong track record in strategy, business development and commercial management, including working with a number of investors, biotech start-ups and SMEs. He is currently a Non-Executive Director at Synpromics Ltd, a synthetic biology company that he co-founded. In 2014-2015 he was CEO of Sentintext Therapeutics, a biotech focussed on the development of vaccines for enterviruses. He was also a director of QSpine Limited, which designs, manufactures and distributes surgical spine medical devices. David has been Chairman of Ambicare Health Limited, CEO of Tayside Flow Technologies Ltd and formerly worked at Chiron Vaccines (now part of Novartis), Acambis plc (now part of Sanofi), and GlaxoSmithKline.


Management

Dr Neil Murray (CEO), as above

Photo of Dr Derek Lindsay (COO)Dr Derek Lindsay (COO), a co-founder of the business, is the Chief Operating Officer having joined the Company full-time in 2012. Derek was previously Director of Innovation of pharmaceutical industry consortium Britest Ltd, from 2006 to 2012. Prior to that he was R&D director of Avecia Pharmaceutical Products and had held a series of management roles in a career spanning 21 years; working in R&D, Process Development and Hazards at Avecia and its predecessor businesses, Zeneca and ICI, which he joined in 1988, after initially working in R&D at BP from 1985.

Photo of Dr Richard Armer (CSO)Dr Richard Armer (CSO) joined Redx in 2012, becoming Chief Scientific Officer in 2014. He has significant experience in both small biotechnology and large pharmaceutical companies through his roles within Pfizer, Organon, Ardana, Oxagen, Lectus Therapeutics. Richard's expertise is in drug discovery with a particular focus on lead optimisation activities, drug disposition, intellectual property and commercial scientific project positioning. He has experience across a wide range of therapeutic areas and has been successful in generating and progressing multiple clinical candidates.

Photo of Nicholas Adams (CBO)Nicholas Adams (CBO) joined as the Company's first Chief Business Officer at the end of 2015. Nick has over 25 years' experience in the pharmaceutical industry, and in particular in business development. He has led a wide range of deal types, including in- and out-licensing, divestments, royalty buy-outs as well as M&A. He has also worked in clinical development in large and mid-sized pharmaceutical companies and in biotech. Most recently, he was Chief Business Officer of Clavis Pharma ASA, the Norwegian drug development company specialising in oncology. Prior to that, he was Vice President of Business Development at Antisoma Research plc, which developed therapies for cancer and autoimmune disease.

Photo of Dr Matilda Bingham (Executive Director Oncology and Immunology)Dr Matilda Bingham (Executive Director Oncology and Immunology) has 14 years’ experience in drug discovery and joined the company in 2012. Matilda’s scientific background is in medicinal chemistry having worked at Organon, Schering-Plough and Merck (MSD) before joining the management team at Redx Pharma. Matilda played a key role in setting up the Redx Oncology subsidiary including laboratory design, recruitment, development of health and safety policies and the creation of the current project portfolio. In 2015 she was promoted from Head of Chemistry to Executive Director and currently manages the Oncology and Immunology subsidiaries.

Photo of Dr Karl Hård (Head of Investor Relations and Corporate Communications)Dr Karl Hård (Head of Investor Relations and Corporate Communications) has spent almost 20 years at AstraZeneca, the last nine of which included senior roles within Investor Relations, latterly as Vice President. Before that, he worked as Global Programme Director, establishing new external collaborations, and as Director in Biological Chemistry, leading research into novel pharmacological targets. His scientific experience covers oncology, immunology and infection.

Karl was Assistant Professor in Chemistry at Leiden University, The Netherlands, and holds a PhD in Chemistry from Utrecht University, and an MSc in Biochemistry from Helsinki University, Finland.

Photo of Andrew Booth (Interim Finance Director)Andrew Booth (Interim Finance Director) holds a degree in Law from Liverpool University, and is a qualified member of the Institute of Chartered Accountants in England & Wales. His areas of expertise include listed company work and International Financial Reporting Standards. Andrew started his career with PKF (now BDO LLP), before moving to work in industry, taking on a number of senior financial roles in AIM and Euronext listed companies (including that of Company Secretary). He joined Redx Pharma as Group Financial Controller in July 2015 and became Interim Finance Director in September 2016.